Form 4: Denali Therapeutics Director David Schenkein Boosts Stake with New Equity Grants and Stock Options

Denali Therapeutics Inc. Director David P. Schenkein has increased his beneficial ownership through the acquisition of 6,037 Restricted Stock Units and 18,111 stock options, aligning his interests further with shareholders.

Summary

• David P. Schenkein, a Director of Denali Therapeutics Inc. (DNLI), acquired 6,037 shares of common stock in the form of Restricted Stock Units (RSUs) and 18,111 stock options on June 3, 2025.
• The RSUs were acquired at a price of $0 per share, representing a contingent right to receive one share of common stock per RSU.
• The stock options have an exercise price of $13.93 per share and expire on June 3, 2035.
• Both the RSUs and stock options are subject to a vesting schedule where 100% will vest upon the earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• Following these transactions, Mr. Schenkein's direct beneficial ownership includes 15,257 shares of common stock (including 6,037 unvested RSUs) and 18,111 stock options.
• Indirect beneficial ownership includes 26,232 shares held by the David P. Schenkein 2004 Revocable Trust and 31,232 shares held by the Amy P. Schenkein 2004 Revocable Trust.

Sentiment

Score: 7

Explanation: The acquisition of additional equity and options by a director is a positive signal, indicating continued confidence and alignment with the company's long-term prospects. It's not a 'strong buy' signal as it's a compensation grant rather than an open market purchase, but it's certainly not negative.

Positives

• Director David P. Schenkein acquired 6,037 Restricted Stock Units (RSUs) and 18,111 stock options, increasing his direct stake in Denali Therapeutics Inc.
• The acquisition of equity and options at a $0 cost for RSUs and an exercise price of $13.93 for options aligns the director's financial interests with the long-term performance of the company and its shareholders.
• The vesting schedule for both RSUs and options encourages long-term commitment and performance from the director.

Future Outlook

NA

Industry Context

This Form 4 filing reflects a routine insider equity grant, common in the biotechnology and pharmaceutical sectors as a form of executive and director compensation, aiming to align leadership incentives with shareholder value creation. It does not provide broader industry trends.

Comparison to Industry Standards

• The grant of Restricted Stock Units and stock options to a director is a standard compensation practice across the biotechnology and pharmaceutical industries, comparable to how companies like Biogen Inc. (BIIB) or Amgen Inc. (AMGN) structure their executive and director equity incentives to foster long-term commitment and performance.
• The vesting schedule, tied to a one-year anniversary or the next annual meeting, is also a common mechanism to ensure retention and performance alignment.

Related Party Transactions

• The reporting person's indirect beneficial ownership includes shares held by the David P. Schenkein 2004 Revocable Trust and the Amy P. Schenkein 2004 Revocable Trust, for which the reporting person or their spouse serves as a trustee.

Stakeholder Impact

• Shareholders: Positive impact as the director's increased equity stake aligns his interests with shareholder value creation.
• Employees: Indirectly positive as strong leadership alignment can contribute to company stability and growth.

Next Steps

• Vesting of 6,037 Restricted Stock Units upon the earlier of the one-year anniversary of the grant date (June 3, 2026) or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• Vesting of 18,111 stock options upon the earlier of the one-year anniversary of the grant date (June 3, 2026) or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Key Dates

Recommendation

Keywords

Denali Therapeutics, DNLI, SEC Form 4, insider transaction, Restricted Stock Units, RSU, stock options, equity grant, beneficial ownership, director compensation, corporate governance